Partial and transient clinical response to omalizumab in IL-21-Induced Low STAT3-Phosphorylation on Hyper-IgE Syndrome

Cesar Daniel Alonso-Bello; María Del Carmen Jiménez-Martínez; María Eugenia Vargas-Camaño; Sagrario Hierro-Orozco; Mario Alberto Ynga-Durand; Laura Berrón-Ruiz; Julio César Alcántara-Montiel; Leopoldo Santos-Argumedo; Diana Andrea Herrera-Sánchez; Fernando Lozano-Patiño; María Isabel Castrejón-Vázquez

doi:10.1155/2019/6357256

Partial and transient clinical response to omalizumab in IL-21-Induced Low STAT3-Phosphorylation on Hyper-IgE Syndrome

Cesar Daniel Alonso-Bello, María Del Carmen Jiménez-Martínez, María Eugenia Vargas-Camaño, Sagrario Hierro-Orozco, Mario Alberto Ynga-Durand, Laura Berrón-Ruiz, Julio César Alcántara-Montiel, Leopoldo Santos-Argumedo, Diana Andrea Herrera-Sánchez, Fernando Lozano-Patiño, María Isabel Castrejón-Vázquez

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Hyper-IgE syndrome (HIES) is a rare primary immunodeficiency characterized by elevated levels of immunoglobulin E (IgE), eczematous dermatitis, cold abscesses, and recurrent infections of the lung and skin caused by Staphylococcus aureus. The dominant form is characterized by nonimmunologic features including skeletal, connective tissue, and pulmonary abnormalities in addition to recurrent infections and eczema. Omalizumab is a humanized recombinant monoclonal antibody against IgE. Several studies reported clinical improvement with omalizumab in patients with severe atopic eczema with high serum IgE level. We present the case of a 37-year-old male with HIES and cutaneous manifestations, treated with humanized recombinant monoclonal antibodies efalizumab and omalizumab. After therapy for 4 years, we observed diminished eczema and serum IgE levels.

Original language	English (US)
Article number	6357256
Journal	Case Reports in Immunology
Volume	2019
DOIs	https://doi.org/10.1155/2019/6357256
State	Published - 2019
Externally published	Yes

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.1155/2019/6357256

Cite this

Alonso-Bello, C. D., Jiménez-Martínez, M. D. C., Vargas-Camaño, M. E., Hierro-Orozco, S., Ynga-Durand, M. A., Berrón-Ruiz, L., Alcántara-Montiel, J. C., Santos-Argumedo, L., Herrera-Sánchez, D. A., Lozano-Patiño, F., & Castrejón-Vázquez, M. I. (2019). Partial and transient clinical response to omalizumab in IL-21-Induced Low STAT3-Phosphorylation on Hyper-IgE Syndrome. Case Reports in Immunology, 2019, Article 6357256. https://doi.org/10.1155/2019/6357256

Alonso-Bello, CD, Jiménez-Martínez, MDC, Vargas-Camaño, ME, Hierro-Orozco, S, Ynga-Durand, MA, Berrón-Ruiz, L, Alcántara-Montiel, JC, Santos-Argumedo, L, Herrera-Sánchez, DA, Lozano-Patiño, F & Castrejón-Vázquez, MI 2019, 'Partial and transient clinical response to omalizumab in IL-21-Induced Low STAT3-Phosphorylation on Hyper-IgE Syndrome', Case Reports in Immunology, vol. 2019, 6357256. https://doi.org/10.1155/2019/6357256

@article{1d16d528891d46dc8f7dc1815815992b,

title = "Partial and transient clinical response to omalizumab in IL-21-Induced Low STAT3-Phosphorylation on Hyper-IgE Syndrome",

abstract = "Hyper-IgE syndrome (HIES) is a rare primary immunodeficiency characterized by elevated levels of immunoglobulin E (IgE), eczematous dermatitis, cold abscesses, and recurrent infections of the lung and skin caused by Staphylococcus aureus. The dominant form is characterized by nonimmunologic features including skeletal, connective tissue, and pulmonary abnormalities in addition to recurrent infections and eczema. Omalizumab is a humanized recombinant monoclonal antibody against IgE. Several studies reported clinical improvement with omalizumab in patients with severe atopic eczema with high serum IgE level. We present the case of a 37-year-old male with HIES and cutaneous manifestations, treated with humanized recombinant monoclonal antibodies efalizumab and omalizumab. After therapy for 4 years, we observed diminished eczema and serum IgE levels.",

author = "Alonso-Bello, {Cesar Daniel} and Jim{\'e}nez-Mart{\'i}nez, {Mar{\'i}a Del Carmen} and Vargas-Cama{\~n}o, {Mar{\'i}a Eugenia} and Sagrario Hierro-Orozco and Ynga-Durand, {Mario Alberto} and Laura Berr{\'o}n-Ruiz and Alc{\'a}ntara-Montiel, {Julio C{\'e}sar} and Leopoldo Santos-Argumedo and Herrera-S{\'a}nchez, {Diana Andrea} and Fernando Lozano-Pati{\~n}o and Castrej{\'o}n-V{\'a}zquez, {Mar{\'i}a Isabel}",

note = "Publisher Copyright: {\textcopyright} 2019 Cesar Daniel Alonso-Bello et al.",

year = "2019",

doi = "10.1155/2019/6357256",

language = "English (US)",

volume = "2019",

journal = "Case Reports in Immunology",

issn = "2090-6609",

publisher = "Hindawi Limited",

}

TY - JOUR

T1 - Partial and transient clinical response to omalizumab in IL-21-Induced Low STAT3-Phosphorylation on Hyper-IgE Syndrome

AU - Alonso-Bello, Cesar Daniel

AU - Jiménez-Martínez, María Del Carmen

AU - Vargas-Camaño, María Eugenia

AU - Hierro-Orozco, Sagrario

AU - Ynga-Durand, Mario Alberto

AU - Berrón-Ruiz, Laura

AU - Alcántara-Montiel, Julio César

AU - Santos-Argumedo, Leopoldo

AU - Herrera-Sánchez, Diana Andrea

AU - Lozano-Patiño, Fernando

AU - Castrejón-Vázquez, María Isabel

PY - 2019

Y1 - 2019

N2 - Hyper-IgE syndrome (HIES) is a rare primary immunodeficiency characterized by elevated levels of immunoglobulin E (IgE), eczematous dermatitis, cold abscesses, and recurrent infections of the lung and skin caused by Staphylococcus aureus. The dominant form is characterized by nonimmunologic features including skeletal, connective tissue, and pulmonary abnormalities in addition to recurrent infections and eczema. Omalizumab is a humanized recombinant monoclonal antibody against IgE. Several studies reported clinical improvement with omalizumab in patients with severe atopic eczema with high serum IgE level. We present the case of a 37-year-old male with HIES and cutaneous manifestations, treated with humanized recombinant monoclonal antibodies efalizumab and omalizumab. After therapy for 4 years, we observed diminished eczema and serum IgE levels.

AB - Hyper-IgE syndrome (HIES) is a rare primary immunodeficiency characterized by elevated levels of immunoglobulin E (IgE), eczematous dermatitis, cold abscesses, and recurrent infections of the lung and skin caused by Staphylococcus aureus. The dominant form is characterized by nonimmunologic features including skeletal, connective tissue, and pulmonary abnormalities in addition to recurrent infections and eczema. Omalizumab is a humanized recombinant monoclonal antibody against IgE. Several studies reported clinical improvement with omalizumab in patients with severe atopic eczema with high serum IgE level. We present the case of a 37-year-old male with HIES and cutaneous manifestations, treated with humanized recombinant monoclonal antibodies efalizumab and omalizumab. After therapy for 4 years, we observed diminished eczema and serum IgE levels.

UR - http://www.scopus.com/inward/record.url?scp=85096771218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85096771218&partnerID=8YFLogxK

U2 - 10.1155/2019/6357256

DO - 10.1155/2019/6357256

M3 - Article

C2 - 31355024

AN - SCOPUS:85096771218

SN - 2090-6609

VL - 2019

JO - Case Reports in Immunology

JF - Case Reports in Immunology

M1 - 6357256

ER -

Partial and transient clinical response to omalizumab in IL-21-Induced Low STAT3-Phosphorylation on Hyper-IgE Syndrome

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this